Sage Therapeutics Inc Net Income per Employee (SAGE), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Sage Therapeutics Inc   (NASDAQ: SAGE)
 

Sage Therapeutics Inc Net Income per Employee

SAGE's Quarterly Results, Trends, Rankings, Statistics
Sage Therapeutics Inc recorded a cumulative net loss of $-301 million during 12 month ending in the second quarter 2025.
The Healthcare sector has seen employees of 230 other companies achieving higher income per employee. While Sage Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 3407 to 3932.


What is Income per Employee Ratio?






SAGE Net Income per Employee (Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
(Dec 31 2024)
IV. Quarter
(Sep 30 2024)
III. Quarter
(Jun 30 2024)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -853,244 -1,003,958 -1,135,031 -956,357 -1,262,530
SAGE's Total Ranking # 3932 # 3407 # 3566 # 3453 # 0
Seq. Net Income Change - - - - -


SAGE Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 231
Healthcare Sector # 607
Overall Market # 3932

Net Income per Employee Statistics
High Average Low
$ 1,887,113 $ -727,363 $ -1,927,020
(Jun 30 2021)   (Dec 31 2019)







Companies with similar Income per Employee for 12 month ending Jun 30 2025, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2025Number of Employees Jun 30 2025


Date modified: 2026-09-08T20:43:11+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.